Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and ...
The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to ...
Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic ...
A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments.
Explore the complexities of insulin biosimilars, their safety, and the impact on diabetes management in global health systems ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029. Samsung Bioepis will ...
After receiving 3 complete response letters, Alvotech has officially received US approval for its adalimumab biosimilar (AVT02; Simlandi), making it the first approval for the company, the 10th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results